# A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19)

> **NCT06053099** · NA · RECRUITING · sponsor: **Intergroupe Francophone de Cancerologie Thoracique** · enrollment: 300 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer
- EGFR Activating Mutation
- EGFR DEL19
- EGFR L858R

## Interventions

- **OTHER:** Plasma ctDNA
- **OTHER:** FFPE blocks

## Key facts

- **NCT ID:** NCT06053099
- **Lead sponsor:** Intergroupe Francophone de Cancerologie Thoracique
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-22
- **Primary completion:** 2031-10
- **Final completion:** 2031-10
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2024-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06053099

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06053099, "A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06053099. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*